166 related articles for article (PubMed ID: 20181574)
1. Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer.
Rajpar S; Massard C; Laplanche A; Tournay E; Gross-Goupil M; Loriot Y; Di Palma M; Bossi A; Escudier B; Chauchereau A; Fizazi K
Ann Oncol; 2010 Sep; 21(9):1864-1869. PubMed ID: 20181574
[TBL] [Abstract][Full Text] [Related]
2. Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.
Fizazi K; Massard C; Smith M; Rader M; Brown J; Milecki P; Shore N; Oudard S; Karsh L; Carducci M; Damião R; Wang H; Ying W; Goessl C
Eur Urol; 2015 Jul; 68(1):42-50. PubMed ID: 25449207
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
Hu XY; Zou QF; Jin C; Li WD; Chen WS; Ma L
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun; 30(6):1343-6. PubMed ID: 20584674
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
Fizazi K; Lipton A; Mariette X; Body JJ; Rahim Y; Gralow JR; Gao G; Wu L; Sohn W; Jun S
J Clin Oncol; 2009 Apr; 27(10):1564-71. PubMed ID: 19237632
[TBL] [Abstract][Full Text] [Related]
5. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
Lipton A; Cook R; Saad F; Major P; Garnero P; Terpos E; Brown JE; Coleman RE
Cancer; 2008 Jul; 113(1):193-201. PubMed ID: 18459173
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
Saad F; Segal S; Eastham J
Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
[TBL] [Abstract][Full Text] [Related]
7. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials.
Som A; Tu SM; Liu J; Wang X; Qiao W; Logothetis C; Corn PG
Br J Cancer; 2012 Oct; 107(9):1547-53. PubMed ID: 23033003
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.
Tamiya M; Tokunaga S; Okada H; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Matsuura Y; Miyamoto N; Hattori M; Taira K; Daga H; Takeda K; Hirashima T
Clin Lung Cancer; 2013 Jul; 14(4):364-9. PubMed ID: 23276824
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
Lipton A; Cook RJ; Major P; Smith MR; Coleman RE
Oncologist; 2007 Sep; 12(9):1035-43. PubMed ID: 17914073
[TBL] [Abstract][Full Text] [Related]
10. Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study.
Raje N; Vescio R; Montgomery CW; Badros A; Munshi N; Orlowski R; Hadala JT; Warsi G; Argonza-Aviles E; Ericson SG; Anderson KC
Clin Cancer Res; 2016 Mar; 22(6):1378-84. PubMed ID: 26644410
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
Hirsh V; Major PP; Lipton A; Cook RJ; Langer CJ; Smith MR; Brown JE; Coleman RE
J Thorac Oncol; 2008 Mar; 3(3):228-36. PubMed ID: 18317064
[TBL] [Abstract][Full Text] [Related]
12. A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [
Vaishampayan UN; Tehrani OS; Lawhorn-Crews JM; Heilbrun LK; Dobson K; Smith D; Dickow B; Shields AF
Mol Imaging Biol; 2017 Dec; 19(6):810-816. PubMed ID: 28289967
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial.
Okegawa T; Higaki M; Matsumoto T; Kase H; Murata A; Noda K; Noda H; Asaoka H; Oshi M; Tomoishi J; Uchida H; Higashihara E; Nutahara K;
Anticancer Res; 2014 Aug; 34(8):4415-20. PubMed ID: 25075079
[TBL] [Abstract][Full Text] [Related]
14. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
Lipton A; Cook R; Brown J; Body JJ; Smith M; Coleman R
Clin Oncol (R Coll Radiol); 2013 Apr; 25(4):217-26. PubMed ID: 23219232
[TBL] [Abstract][Full Text] [Related]
15. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.
Broom RJ; Hinder V; Sharples K; Proctor J; Duffey S; Pollard S; Fong PC; Forgeson G; Harris DL; Jameson MB; O'Donnell A; North RT; Deva S; Hanning FJ; Grey A; Findlay MP
Clin Genitourin Cancer; 2015 Feb; 13(1):50-8. PubMed ID: 25163397
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
Smith MR; Halabi S; Ryan CJ; Hussain A; Vogelzang N; Stadler W; Hauke RJ; Monk JP; Saylor P; Bhoopalam N; Saad F; Sanford B; Kelly WK; Morris M; Small EJ
J Clin Oncol; 2014 Apr; 32(11):1143-50. PubMed ID: 24590644
[TBL] [Abstract][Full Text] [Related]
17. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.
Cook RJ; Coleman R; Brown J; Lipton A; Major P; Hei YJ; Saad F; Smith MR
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3361-7. PubMed ID: 16740758
[TBL] [Abstract][Full Text] [Related]
18. Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.
Lipton A; Smith MR; Fizazi K; Stopeck AT; Henry D; Brown JE; Shore ND; Saad F; Spencer A; Zhu L; Warner DJ
Clin Cancer Res; 2016 Dec; 22(23):5713-5721. PubMed ID: 27140926
[TBL] [Abstract][Full Text] [Related]
19. Utility of urinary type I collagen cross-linked N-telopeptide as a prognostic indicator in breast cancer patients with bone metastases.
Shizuku M; Shibata M; Okumura M; Takeuchi D; Kikumori T; Mizuno Y
Breast Cancer; 2020 Nov; 27(6):1065-1071. PubMed ID: 32415556
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]